Initiator Pharma – Screening ongoing and first dosing expected soon in Phase 2a trial with IP2018
Initiator Pharma A/S, a clinical-stage biotech company today announced that the screening of patients for the Phase 2a clinical trial with IP2018 is still ongoing and the first dosing of patients is expected shortly.Initiator Pharma has been made aware of that, in the recently published teaser for the ongoing exercise period for the warrants of series TO 2, there is information on the Phase 2a clinical trial with IP2018 stating both that the dosing of the first patient is expected shortly - and that the first patient already has been dosed. The correct information is, as previously